EZN-2285
| EZN-2285 | |
|---|---|
| Term | EZN-2285 |
| Short definition | EZN-2285 - A medicine used with other medicines to treat acute lymphoblastic leukemia in children and young adults aged 1 month to 21 years. It is also being studied in the treatment of other types of cancer. |
| Type | Cancer terms |
| Specialty | Oncology |
| Language | English |
| Source | NCI |
| Comments | |
EZN-2285 - A medicine used with other medicines to treat acute lymphoblastic leukemia in children and young adults aged 1 month to 21 years. It is also being studied in the treatment of other types of cancer. EZN-2285 consists of the enzyme L-asparaginase linked to a substance called SC-PEG, which allows the drug to stay in the body longer. L-asparaginase comes from the bacterium E. coli and breaks down the amino acid asparagine. This can stop the growth of cancer cells that need asparagine to grow. EZN-2285 is a type of protein synthesis inhibitor. Also called Asparlas, Calaspargase Pegol and SC-PEG E. coli L-Asparaginase
External links
- Medical encyclopedia article on EZN-2285
- Wikipedia's article - EZN-2285
This WikiMD dictionary article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski